ArticleCancers2022

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.

Nadja Sailer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.